Biology and Therapy of Non-Muscle Invasive Bladder Cancer Symposium (2018)
Recent genomic studies have provided a much more granular view of the biological and clinical heterogeneity of muscle-invasive cancers, and clinical trials employing anti-PD1 and anti-PDL1 antibodies have demonstrated that these agents have unprecedented clinical activity in advanced disease. Although it is a much more prevalent form of the disease, much less is known about the biological heterogeneity of non-muscle invasive cancer and how this heterogeneity might affect clinical progression patterns and responses to intravesical and systemic therapy.
The overarching goal of this meeting is to bring together the thought leaders in the field and other interested experts to critically review the “state of the science” and the clinical trials portfolio in non-muscle invasive bladder cancer and to begin to establish consensus for future efforts.
After completing this activity, particpants will be able to:
- Describe the “state of the science” in non-muscle invasive bladder cancer.
- Summarize ongoing and planned clinical trials in patients with non-muscle invasive bladder cancer.
- Synthesize current approaches to begin to establish consensus for future efforts in treating non-muscle invasive bladder cancer.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 9.25 AMA PRA Category 1 Credit™
- 9.25 Non-Physician Participation